Bank of New York Mellon
RANI icon

Bank of New York Mellon’s Rani Therapeutics RANI Stock Holding History

Bank of New York Mellon’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Hold
13,879
– – ﹤0.01% 4278
2026
Q1 		$10.2K Buy
+13,879
New +$17.7K ﹤0.01% 4187

Other funds holding RANI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
WDL
Well Done LLC Holland, Michigan $743M AUM 22.58% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
M
MOTCO San Antonio, Texas $1.17B AUM 23.84% 1-Year Est. Return

Bank of New York Mellon's RANI Position: Q2 2026 in Review

Bank of New York Mellon held its Rani Therapeutics (RANI) position steady in Q2 2026 at 13,879 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4278.

Bank of New York Mellon first reported a position in RANI in Q1 2026 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Bank of New York Mellon held 13,879 shares of Rani Therapeutics worth $10.6K as of Q2 2026.
  • Bank of New York Mellon left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4278 holding.
  • Bank of New York Mellon first reported a position in Rani Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.